Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University Health Network, Toronto Susan G. Komen Breast Cancer Foundation Dr. Julia Knight (research collaborator) |
---|---|
Information provided by: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT00188760 |
The purpose of this study is to test the ability of a technique called Transillumination Breast Spectroscopy (TIBS) to monitor an individual's breast density changes over time.
Condition |
---|
Breast Cancer |
Study Type: | Observational |
Study Design: | Case Control, Prospective |
Official Title: | Optical Quantification of Breast Density Changes Due to Hormone Treatment, Pregnancy and Breast-Feeding. |
Estimated Enrollment: | 300 |
Study Start Date: | May 2004 |
Estimated Study Completion Date: | September 2010 |
Breast density is an established physical risk factor for breast cancer, applicable to the entire female population in a pre-breast-screening program and, unlike other risk factors, was shown to be affected by an intervention treatment. High breast tissue density is associated with increased risk of breast cancer. Transillumination Breast Spectroscopy (TIBS) uses a white light to provide spectral information on breast tissue density and composition (e.g. water, lipid, hemoglobin and other biomolecules). The overall goal of the TIBS program is to develop a technique that can identify individuals at high risk for breast cancer who would benefit most from improved screening methods and a risk reducing intervention (e.g. diet and lifestyle changes) and can monitor the efficacy of the risk reducing intervention itself in an individual. In a previous study, we demonstrated a high correlation between breast density assessed by TIBS and density identified by x-ray mammography. The current study is testing TIBS ability to monitor changes in an individual's breast density over time
Ages Eligible for Study: | 25 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Cases recruited from the Reproductive Biology Unit at Mount Sinai Hospital and the University Health Network community. Controls recruited from University Health Network community and the University of Toronto community. (Toronto, Ontario, Canada)
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
Ontario Cancer Institute, Princess Margaret Hospital | |
Toronto, Ontario, Canada, M5G 2M9 |
Principal Investigator: | Lothar Lilge, PhD | Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada M5G 2M9; Department of Biophysics and Bioimaging, University of Toronto, Ontario, Canada M5G 2M9 |
Study ID Numbers: | UHNREB#02-0712-C, SGKBCF#BCTR0402530, MSHREB#02-0226-E, UTREB#9313, HC#69745 |
Study First Received: | September 9, 2005 |
Last Updated: | November 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00188760 |
Health Authority: | Canada: Health Canada |
Breast Transillumination Spectroscopy Optical Transillumination Spectroscopy Breast Cancer Risk |
Skin Diseases Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site |